PMID- 21747826
OWN - NLM
STAT- MEDLINE
DCOM- 20111202
LR  - 20220321
IS  - 1687-5303 (Electronic)
IS  - 1687-5214 (Print)
IS  - 1687-5214 (Linking)
VI  - 2011
DP  - 2011
TI  - Glucagon-like peptide-1, diabetes, and cognitive decline: possible 
      pathophysiological links and therapeutic opportunities.
PG  - 281674
LID - 10.1155/2011/281674 [doi]
LID - 281674
AB  - Metabolic and neurodegenerative disorders have a growing prevalence in Western 
      countries. Available epidemiologic and neurobiological evidences support the 
      existence of a pathophysiological link between these conditions. Glucagon-like 
      peptide 1 (GLP-1), whose activity is reduced in insulin resistance, has been 
      implicated in central nervous system function, including cognition, synaptic 
      plasticity, and neurogenesis. We review the experimental researches suggesting 
      that GLP-1 dysfunction might be a mediating factor between Type 2 diabetes 
      mellitus (T2DM) and neurodegeneration. Drug treatments enhancing GLP-1 activity 
      hold out hope for treatment and prevention of Alzheimer's disease (AD) and 
      cognitive decline.
FAU - Mossello, Enrico
AU  - Mossello E
AD  - Unit of Gerontology and Geriatric Medicine, Department of Critical Care Medicine 
      and Surgery, University of Florence and Careggi Teaching Hospital, 50121 
      Florence, Italy. enrico.mossello@unifi.it
FAU - Ballini, Elena
AU  - Ballini E
FAU - Boncinelli, Marta
AU  - Boncinelli M
FAU - Monami, Matteo
AU  - Monami M
FAU - Lonetto, Giuseppe
AU  - Lonetto G
FAU - Mello, Anna Maria
AU  - Mello AM
FAU - Tarantini, Francesca
AU  - Tarantini F
FAU - Baldasseroni, Samuele
AU  - Baldasseroni S
FAU - Mannucci, Edoardo
AU  - Mannucci E
FAU - Marchionni, Niccolo
AU  - Marchionni N
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20110601
PL  - United States
TA  - Exp Diabetes Res
JT  - Experimental diabetes research
JID - 101274844
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
SB  - IM
MH  - Animals
MH  - Cognition Disorders/*etiology/metabolism/physiopathology/prevention & control
MH  - Diabetes Mellitus, Type 2/*complications/*drug 
      therapy/metabolism/*physiopathology
MH  - Endocrinology/methods/trends
MH  - Glucagon-Like Peptide 1/deficiency/metabolism/*physiology/therapeutic use
MH  - Humans
MH  - Insulin Resistance/physiology
MH  - Nerve Degeneration/drug therapy/etiology/metabolism
MH  - Therapies, Investigational/methods/trends
PMC - PMC3124026
EDAT- 2011/07/13 06:00
MHDA- 2011/12/13 00:00
PMCR- 2011/06/01
CRDT- 2011/07/13 06:00
PHST- 2011/02/25 00:00 [received]
PHST- 2011/04/05 00:00 [accepted]
PHST- 2011/07/13 06:00 [entrez]
PHST- 2011/07/13 06:00 [pubmed]
PHST- 2011/12/13 00:00 [medline]
PHST- 2011/06/01 00:00 [pmc-release]
AID - 10.1155/2011/281674 [doi]
PST - ppublish
SO  - Exp Diabetes Res. 2011;2011:281674. doi: 10.1155/2011/281674. Epub 2011 Jun 1.